Novo Nordisk announced that the FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of… read more.
UK organisations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law,… read more.
Overweight or obese adults lost more weight and shed pounds faster using Mounjaro than those taking Novo Nordisk’s rival weight loss drug (Wegovy/Ozempic)) according to an analysis of… read more.
Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up… read more.
Deborah Evans is Superintendent Pharmacist and Clinic Director at Remedi Health, where she runs a weight management service, including the provision of semaglutide. In this series of short… read more.
People seeking semaglutide for weight management from a pharmacy-led service need to feel assured that the service is ethical and legal and has the best interests of the… read more.
Taking time to understand a patient’s weight loss goals and checking their medical history to ensure there are no underlying problems that may need onward referral are both… read more.
Online supply of semaglutide makes the medicine more accessible but may not provide the best support or guidance to enable people to get the best out of the… read more.
Wegovy and Ozempic both contain semaglutide but are authorised for different indications. They are also presented in slightly different concentrations and dose schedules, explains Deborah Evans, Superintendent Pharmacist… read more.
Deborah Evans is superintendent pharmacist and clinic director at Remedi Health, an independent pharmacy and healthcare clinic in Winchester. Remedi Health runs a weight management service and has… read more.
Results from the STEP 5 phase IIIb trial, presented by Novo Nordisk at the Obesity Week 2021 interactive congress, showed that adults treated with Wegovy (semaglutide 2.4 mg… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
